Diagnosticos da America S.A.BMFBOVESPA: DASA3

Diagnósticos da América: Dasa posted double-digit EBITDA growth and closed its transformative joint venture with Amil

· Issued by Diagnosticos da America S.A.

Dasa delivered strong 1Q25 results with 11% EBITDA growth, margin expansion, and reduced net loss, while closing a major joint venture with Amil and maintaining disciplined capital allocation. Leverage and liquidity remain stable, supporting long-term value creation.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Diagnosticos da America S.A. on 6ix

Story so far

Earlier from Diagnosticos da America

Later from Diagnosticos da America

All Diagnosticos da America news releases